20results about How to "Lower Level Requirements" patented technology

Methods, compositions, and systems for steeping, propagation and fermentation, particularly large-scale operations for production of starch and ethanol and fermentation product streams are provided. Addition of mycotoxin mitigating enzymes or microorganisms expressing mycotoxin mitigating enzymes to steeping, propagation, and / or fermentation tanks, and / or to post-fermentation product streams, mitigates mycotoxin levels in fermentation co-products obtained from mycotoxin contaminated feedstocks.

The invention discloses a full-automatic single-chip microbiological detection system. The system comprises a micro-fluidic chip, a cam mechanism, a pressing module for driving the cam mechanism to do reciprocating rectilinear motion, a first on-off assembly and a second on-off assembly, during working, the pressing module drives the cam mechanism, the first on-off assembly and the second on-off assembly to linearly move to approach the micro-fluidic chip, the second on-off assembly controls the micro-fluidic chip to be communicated with the atmosphere, and the cam mechanism sequentially controls the first on-off assembly to open or close a flow channel on the micro-fluidic chip. Controlling the solution to be transferred into a target chamber for a microbiological detection experiment; various solutions are quantitatively filled into the storage cavity in the micro-fluidic chip in advance, the corresponding solutions are controlled to be transferred into the target cavity for experiments in different experiment steps based on cooperation of a cam structure, the on-off puncture assembly and the like, reagent bottles and pipelines do not need to be externally connected, operation is easy and convenient, stability is good, and reliability is high.

A GLP-1 / GIP dual-targeted polypeptide, containing a first polypeptide having the following amino acid sequence : X1X2X3GT FX4SDY SX5X6X7X8 X9X10X11X12X13 X14FX15X16W LX17X18X19, wherein X1 is Y or H, X2 is A or G or S, X3 is E or Q, X4 is I or T, X5 is I or K, X6 is A or Y or L or I, X7 is M or L, X8 is D or E, X9 is K or E, X10 is I or Q or K or E or L, X11 is H or A or R, X12 is A or Q or V, X13 is K or Q or R or H, X14 is D or E or A or L, X15 is V or I, X16 is N or E or D or Q, X17 is L or I or K or V, X18 is A or E or K, X19 is Q or G; X1~X13 do not satisfy at the same time that X1 is Y, X2 is A, X3 is E, X4 is I, X5 is I, X6 is A, X7 is M, X8 is D, X9 is K, X10 is I, X11 is H, X12 is Q, X13 is Q, X14 is D, X15 is V, X16 is N, X17 is L, X18 is A, X19 is Q. The GLP-1 / GIP dual-targeted polypeptide can effectively reduce the weight and blood sugar level.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

An siRNA targeting 17β-hydroxysteroid dehydrogenase type 13 and a siRNA conjugate. Also disclosed are a pharmaceutical composition, cell or kit containing the siRNA, and a method for using the siRNA for the treatment and / or prevention of subjects suffering from HSD17B13-related disorders (such as chronic fibroinflammatory liver disease).

The present invention relates to Lactobacillus rhamnosus, Bifidobacterium longum, and Lactococcus lactis, which are novel lactic acid bacteria. The strains according to the present invention have high utility as a medicine or food and, in particular, can be used for preventing, treating, or relieving inflammatory diseases and neurological diseases, due to having an excellent antioxidant effect, inflammation-relieving effect, nerve-improving effect, cognition-improving effect, intestinal microbiota imbalance-improving effect, etc. In addition, the present invention can be used for regulating and enhancing immunity by increasing the activity of the immune system through immune function-improving and immunity-enhancing effects.

The present invention belongs to the field of medicine, and relates to a compound of Formula I and a pharmaceutically acceptable salt thereof for using as a MAGL inhibitor, as well as a preparation method and use thereof, and an intermediate for preparing the same.

Some embodiments comprise a pump assembly for reduced pressure wound therapy, comprising a housing, a flow pathway through the pump, one or more valves in communication with the flow pathway, a pump supported within or by the housing, and a one-way flow valve in fluid communication with the pump. The pump assembly can have a pressure sensor in communication with the flow pathway through the pump, and at least one switch or button supported by the housing, the at least one switch or button being accessible to a user and being in communication with the controller. The one-way flow valve can be configured to substantially prevent a flow of gas through the one-way flow valve in a direction of flow away from the pump. The pump assembly can have a controller supported within or by the housing, the controller being configured to control an operation of the pump. The pump has been sterilized following the assembly of the pump such that an inside and an outside of the housing, the flow pathway, the one or more valves, the pump, the controller, the battery compartment, and the at least one switch or button have been sterilized.

The present invention relates to methods for treating a human patient suffering from acute kidney injury.

Disclosed in the present invention are a CLY series compound, a preparation method therefor and the use thereof in the preparation of drugs. The CLY series compound is a compound with a structure of formula I, a tautomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. Animal model experiments show that the CLY series compound, in a chloasma mouse model, can obviously reduce the level oftyrosinase in the skin and blood, reduce the expression of the stem cell factor (SCF) and C-Kit protein in the skin, and inhibit the chromogenesis of chloasma, can obviously promote the healing of a wound on skin and reduce the formation of scars, in a hair loss mouse model, can obviously promote the hair growth and reduce damage to hair follicles, and in a rabbit ear acne model, can obviously reduce the symptoms and reduce pore blockage and acne formation. The CLY series compound can significantly prolong the survival time of acute GVHD mice, and can reduce clinical symptoms, exhibiting a therapeutic effect on acute GVHD; in a pulmonary fibrosis mouse model, same can obviously reduce the levels ofMMP-2 and MMP-9 in the lung tissue, increase the levels of TIMP-1 and VEGF, and simultaneously increase the levels of SOD and CAT enzymes in peripheral blood; and same can also improve the arthritis symptoms ofrheumatoid arthritis mice by means of reducing the level of IL-17 in peripheral blood and increasing inflammatory indexes such as IL-10. The compound can be used alone or in ombination with other drugs, and provides a new drug choice for the treatment of the above diseases.

Described herein are methods for using compounds that activate pyruvate kinase.

Provided is a noise-cancelling headphone device that prevents deterioration of reproduction frequency characteristics in a high-frequency band while preventing reduction in the reproduction output in the low-frequency band. The proposed technology is a noise-cancelling headphone device, including a speaker unit 4 provided with a dome-shaped diaphragm 2 having a center dome 5 and a sub-dome 6, a microphone 31 that detects ambient noise incident into the speaker unit, a baffle plate 17 supporting the speaker unit and provided with sound emission holes 20, 22 to radiate reproduction sound emitted from the speaker unit, and a signal processing circuit to generate noise cancellation signal generated based on the ambient noise detected by the microphone, wherein an acoustic resistance member 35 is provided at the position facing the sub-dome 6 of the dome diaphragm.

The present disclosure relates to a geranylgeranyl pyrophosphate synthase variant; a polynucleotide encoding the variant; a vector including the polynucleotide; a microorganism including any one or more of the variant, the polynucleotide, and the vector; a method of producing tetraterpene, a precursor thereof, or a material having tetraterpene as a precursor using the same; a composition for producing tetraterpene, a precursor thereof, or a material having tetraterpene as a precursor; and use of the microorganism including any one or more of the variant, the polynucleotide, and the vector, for producing tetraterpene, a precursor thereof, and a material having tetraterpene as a precursor.

The present application belongs to the technical field of board card detection and aging management, and particularly relates to a universal board card automatic detection device. An upper computer formulates a board card test procedure, generates a control instruction, controls other units to work in coordination to complete function test, simulation test and dynamic impedance test of the board card, and gives a test report and various statistical results; a power supply provides various input signal power or power supply according to the upper computer instruction. V&I curve and impedance test of digital IC components are completed through a clamp. V&I curve and impedance test of analog components are completed through a probe. Frequency, voltage and current function test of components are completed through a probe. The present application can select appropriate test items according to the characteristics of the board card, the requirements of regulations and actual needs, and the test items can be combined autonomously.

The present invention provides a cannabidiol derivative, a method for preparing same, and a composition for cognitive function improvement comprising same. The novel cannabidiol derivative of the present invention has been confirmed to exhibit acetylcholinesterase inhibitory activity and butyrylcholinesterase inhibitory activity, as well as inhibitory activity against monoamine oxidase B. Therefore, it is possible to simultaneously treat a decrease in acetylcholine levels in brain tissue and a decrease in blood butyrylcholine levels, which are seen in patients with dementia, and to provide a more effective cognitive function improvement treatment by preventing brain cell damage. Therefore, the cannabidiol derivative, the method for preparing same, and the composition for improving cognitive function comprising same, of the present invention, can be usefully used as a substance for improving cognitive function in the field of medicine and dietary supplement that can simultaneously inhibit acetylcholinesterase, butyrylcholinesterase, and monoamine oxidase B.

The present invention relates to an N-substituted phenylsulfonamide compound and a use thereof. Specifically, the present invention provides a compound represented by formula I, or an optical isomer thereof, or a racemate thereof, or a pharmaceutically acceptable salt thereof. The compound described in the present invention has an excellent inhibitory effect on transient receptor potential channel proteins, and has an excellent therapeutic effect on transient receptor potential channel protein-related diseases, such as inflammatory bowel disease, irritable bowel syndrome, pain, and inflammation.

The present invention aims to provide a method for removing glycosylation isomers in antibody drugs, etc. The present invention provides, for example, a purification method for an antibody composition, said method comprising: loading the antibody composition on conventional chromatography to allow an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to a media of the chromatography; and treating the media with an eluent to thereby elute the antibody adsorbed to the media to obtain a purified antibody composition.